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Barriers to adherence to chronic obstructive 
pulmonary disease guidelines by primary  
care physicians
Purpose: Even with the dissemination of several clinical guidelines, chronic obstructive 
  pulmonary disease (COPD) remains underdiagnosed and mismanaged by many primary 
care physicians (PCPs). The objective of this study was to elucidate barriers to consistent 
  implementation of COPD guidelines.
Patients and methods: A cross-sectional study implemented in July 2008 was designed to 
assess attitudes and barriers to COPD guideline usage.
Results: Five hundred US PCPs (309 family medicine physicians, 191 internists) were included 
in the analysis. Overall, 23.6% of the surveyed PCPs reported adherence to spirometry guidelines 
over 90% of the time; 25.8% reported adherence to guidelines related to long-acting bronchodi-
lator (LABD) use in COPD patients. In general, physicians were only somewhat familiar with 
COPD guidelines, and internal medicine physicians were significantly more familiar than family 
physicians (P , 0.05). In a multivariate model controlling for demographics and barriers to 
guideline adherence, we found significant associations with two tested guideline components. 
Adherence to spirometry guidelines was associated with agreement with guidelines, confidence 
in interpreting data, ambivalence to outcome expectancy, and ability to incorporate spirometry 
into patient flow. Adherence to LABD therapy guidelines was associated with agreement with 
guidelines and confidence in gauging pharmacologic response.
Conclusions: Adherence to guideline recommendations of spirometry use was predicted by 
agreement with the recommendations, self-efficacy, perceived outcome expectancy if recom-
mendations were adhered to, and resource availability. Adherence to recommendations of LABD 
use was predicted by agreement with guideline recommendations and self-efficacy. Increasing 
guideline familiarity alone may have limited patient outcomes, as other barriers, such as low 
confidence and outcome expectancy, are more likely to impact guideline adherence.
Keywords: COPD, primary care, barriers, guideline adoption
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of morbidity 
and mortality in the US and affects more than 12 million Americans. This respiratory 
disease is commonly evaluated and managed by primary care physicians (PCPs), 
  particularly when symptoms are of mild-to-moderate severity.1 Several clinical practice 
guidelines offer strategies to optimize care for patients with COPD in the primary care 
setting. These evidence-based resources are free and easily accessible via the Internet. 
Many have been recently issued or updated, integrating new scientific findings and 
reflecting the availability of emerging therapeutic options.
Despite the availability of guidelines, PCPs often manage COPD in a manner that 
is discordant with recommendations. To a degree, this may reflect limited awareness of International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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recommendations, as many PCPs are unfamiliar with COPD 
guidelines.2,3 Yet even among physicians who have some 
guideline familiarity, practice patterns are often inconsistent 
with guideline recommendations.2,3
Guideline implementation to facilitate accurate COPD 
diagnosis is of particular concern. Current guidelines uni-
versally advocate the use of spirometry to confirm a COPD 
diagnosis and to facilitate early intervention. This stance is 
consistent with diagnostic directives that date back more 
than 35 years.4 Despite its longevity, physician adherence to 
this recommendation is subobptimal. COPD is often under-
diagnosed and misdiagnosed in the primary care setting.5 
Marked underutilization of spirometry testing has been well 
documented and is thought to be a contributing factor.2,3,6,7 
Lack of spirometry access undoubtedly contributes to low 
utilization and is a significant problem for some primary care 
practice. Interventions have been designed to overcome this 
barrier by providing equipment and training but have been 
inconsistent in improving spirometry use.8,9 Other influences 
and barriers may be restraining spirometry use and need to 
be better defined and targeted.
Cabana et al have developed a framework that may be 
helpful in explaining and identifying key determinants of 
guideline adherence by physicians.10 Their model was origi-
nally developed to identify determinants of guideline adop-
tion in pediatric asthma,11 but it has been extensively applied 
to elicit potential levers for performance improvement.12,13 
The Cabana model examines commonly studied determi-
nants such as guideline familiarity and barriers to guideline 
  adoption. In addition, the model explores perceptual influ-
ences on behavior, such as attitudes regarding the guideline 
source, as well as the expected benefits of implementing 
specific recommendations.
This framework was applied in the present study to 
explore determinants of COPD guideline adherence or lack 
thereof. Models designed for this study used the evidence-
based guideline developed by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) as a   benchmark.14 
The primary model developed for this study centered on 
diagnostic spirometry use. Directives to use spirometry to 
confirm COPD diagnosis have been relatively stable for an 
extended period, and there is a considerable amount of litera-
ture on spirometry use to inform the model. As a secondary 
focus, we also explored the use of bronchodilator agents 
to treat COPD symptoms. GOLD guidelines recommend 
inhaled bronchodilators as a cornerstone of COPD symptom 
  management; however, PCPs often turn to other agents as 
first-line COPD therapy.1,2 Optimal   pharmacotherapy for 
COPD is a more dynamic area as a result of emerging trial 
data and therapeutic options.
The use of the Cabana framework to explore these two 
aspects of COPD care enables several behavioral influences 
to be examined simultaneously and may provide valuable 
insight about their relative importance. This information 
is expected to facilitate the development of more   effective 
educational and quality improvement interventions in 
COPD care.
Methods
Development and distribution  
of survey instrument
A survey instrument was developed to explore determinants 
of PCP adherence to GOLD guideline recommendations 
on diagnostic spirometry and long-acting bronchodilator 
(LABD) use. The instrument’s domains drew on the Cabana 
guideline adherence framework. Self-reported adherence 
to GOLD recommendations was assessed with two ques-
tions on routine clinical practice behaviors. Physicians 
were asked to rate how often they “order spirometry when 
patients report symptoms that lead you to suspect COPD” 
and how often they “recommend using an inhaled long-
acting bronchodilator daily for patients with COPD and 
mild exertional dypnea”. Adherence was measured using 
five frequency categories (#25% of the time, 26%–50% 
of the time, 51%–75% of the time, 75%–90% of the time, 
and $91% of the time).
Physicians were asked to rate their familiarity and 
perceptions regarding the GOLD guidelines, as well as 
their agreement with specific GOLD recommendations. 
Physicians were also asked to rate the perceived helpfulness 
(outcome expectancy) and their confidence (self-efficacy) 
in implementing the two guideline recommendations of 
interest. The survey used a 10-point Likert scale for respon-
dents to indicate familiarity with guidelines, outcomes 
expectancy, and self-efficacy (1, not at all; 10, extremely). 
A 7-point Likert scale was used to measure agreement with 
guideline statements (1, strongly disagree; 4, neutral; 7, 
strongly agree). Because of space limitations, assessment 
of barriers focused only on spirometry testing. Physicians 
were asked whether they had used an onsite spirometer and 
where they typically send patients who need spirometry 
testing. They were also asked to indicate, in a dichotomous 
manner, whether potential barriers hindered their ability to 
confirm a COPD diagnosis using spirometry. Demographic 
information about physicians and their practice was also 
collected.International Journal of COPD 2011:6
Table 1 Characteristics of survey respondents
Overall 
(n = 500)
Family 
medicine 
(n = 309)
Internal 
medicine 
(n = 191)
Mean years in practice (SD) 16.1 (7.8) 15.7 (7.9) 16.8 (7.6)
Mean patients seen/week  
with COPD (SD)
19.2 (20.8) 17.2 (16.5) 22.5 (26.1)
Male (%) 72.6 71.2 74.9
Work environment (%)
Community-based 
private practice
78.0 76.6 80.1
Academic practice 5.0 4.5 5.8
hMO 1.2 1.6 0.5
hospital-owned practice 11.8 11.4 12.6
Other 4.0 5.8 1.0
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  hMO,  health 
maintenance organization; SD, standard deviation.
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Primary care and pulmonology physicians with rec-
ognized expertise in COPD provided guidance during 
survey development. As an additional quality control 
  measure, the survey was piloted with PCPs using a cogni-
tive interview process. This step identified potential areas of 
ambiguity within the instrument and ensured its relevance to 
community-based clinical practice.
The survey instrument was distributed by email and fax 
in July 2008 to 11,100 PCPs randomly selected from the 
American Medical Association (AMA) Physician Masterfile. 
A small monetary incentive was offered for completion of 
the survey. The first 500 individuals who responded to the 
invitation and met the criteria for inclusion were accepted into 
the study. A power calculation was conducted to determine 
the sufficient sample size (confidence interval of 95%) to 
represent the US PCP population.
Analysis
Descriptive and inferential statistics were conducted on 
all items in the survey using Chi-square (χ2) analysis to 
examine differences between family medicine and internal 
medicine physicians. Binary logistic regression was used 
to predict guideline adherence (SPSS®, Version 17.0; SPSS 
Inc,   Chicago, IL, USA). For the two guideline components 
analyzed, the dependent variable was each physician’s self-
reported level of guideline adherence. Independent variables 
included agreement with guideline statements, guideline 
familiarity level, self-efficacy and outcome expectancy of 
spirometry or LABD use, external barriers to spirometry, 
percentage of patients seen with COPD, gender, specialty, 
and years in practice. For analysis, physicians were consid-
ered to be guideline adherent if they implemented a guideline 
recommendation over 91% of the time, equal to the value 
set by Cabana et al.11 Values were considered significant 
when P , 0.05.
Results
Sample
Table 1 shows the demographic data of the survey respon-
dents. Most of the surveyed physicians practiced in a 
community setting. Internal medicine physicians saw, on 
average, five more patients per week with COPD than did 
family medicine physicians. The surveyed internal medicine 
physicians also had been in practice longer and were more 
likely to be male than the family medicine physicians. When 
compared with characteristics of US PCPs identified from 
the AMA Physician Masterfile, this sample had similar years 
in practice but a higher male representation.
Guideline adherence
A majority of the physicians agreed with guideline state-
ments regarding spirometry and LABD use (Table 2). Over 
two-thirds (69.1%) of PCPs agreed that when COPD is 
suspected, the diagnosis should be confirmed by spirometry; 
78.4% agreed that an LABD should be added for patients 
with stage 2–3 COPD whose dyspnea during daily activities 
is not relieved with an as-needed short-acting bronchodila-
tor. However, only 23.4% of surveyed PCPs indicated that 
they “nearly always” ($91% of the time) order spirometry 
when patients report symptoms suggestive of COPD. Also, 
only 25.8% of the PCPs “nearly always” recommend using 
an LABD daily for patients with COPD and mild exertional 
dyspnea.
Guideline familiarity
Respondents were asked to rate familiarity with various 
guidelines on a 10-point scale. Overall, PCPs were more 
familiar with GOLD guidelines than with American   Thoracic 
Society (ATS)/European Respiratory Society (ERS) or 
American College of Physicians (ACP) guidelines. High 
levels of familiarity with GOLD, ATS/ERS, and ACP 
guidelines and ratings of 8–10 on the 10-point scale were 
more common with internal medicine physicians than with 
family medicine physicians (Figure 1). Nearly one-quarter 
(24.0%) of PCPs were unfamiliar with GOLD guidelines, 
rating familiarity as 1–3 on the 10-point scale; 23.0% were 
unfamiliar with ACP guidelines. One-third (33.2%) of 
respondents were unfamiliar with ATS/ERS guidelines. 
As a comparison, approximately three-quarters of internal 
medicine and family medicine physicians were very familiar 
with the Seventh Report of the Joint National Committee on 
  Prevention, Detection,   Evaluation, and Treatment of High International Journal of COPD 2011:6
Table 2 Adherence and attitudes toward chronic obstructive pulmonary disease (COPD) guidelines
Overall Family medicine Internal medicine P
In your routine clinical practice, how often do you do each of the following?a
Order spirometry when patients report symptoms that lead 
you to expect COPD
23.6% 23.7% 23.0% 0.12
Recommend using an inhaled long-acting bronchodilator 
daily for patients with COPD and mild exertional dyspnea
25.8% 23.9% 28.8% 0.68
Agreement with guideline statementsb
When COPD is suspected, the diagnosis should be 
confirmed by spirometry
69.2% 68.9% 69.5% 0.92
For patients with stage 2–3 COPD whose dyspnea during 
daily activities is not relieved with as-needed short-acting 
bronchodilator, a long-acting bronchodilator should be added
78.2% 79.6% 76.4% 0.43
Notes: aValues indicate percentage of physicians who indicated that they “nearly always” do this action (91%–100% of the time); bValues indicate percentage of physicians 
who “agree” or “strongly agree” with the statements (6–7 on a 7-point scale).
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Figure 1 Familiarity with clinical practice guidelines. Surveyed physicians indicated 
their  familiarity  with  various  clinical  practice  guidelines.  The  percentages  of 
physicians who rated themselves as “very familiar” (rated 8–10 on a 10-point scale) 
are shown. Internal medicine physicians are more familiar with GOLD, ATS/ERS, 
and ACP COPD guidelines than family medicine physicians. however, familiarity 
with the COPD guidelines is much less than familiarity with the JNC 7 hypertension 
guidelines.
Note: *Significance between familiarity of specialties (P , 0.05).
Abbreviations: ACP, American College of Physicians; ATS, American Thoracic 
Society; COPD, chronic obstructive pulmonary disease; ERS, European Respiratory 
Society;  GOLD,  Global  Initiative  for  Chronic  Obstructive  Lung  Disease; 
JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of high Blood Pressure.
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Blood   Pressure (JNC 7) hypertension guidelines, rating 
familiarity as 8–10.   Physicians who care for more patients 
with COPD were more likely to be familiar with all COPD 
guidelines. Physicians who had been in practice for 15 years 
or less were more likely to be familiar with ATS/ERS 
  guidelines but not GOLD guidelines.
Attitudes regarding guideline 
recommendations
A majority of PCPs reported high confidence (8–10 on the 
10-point scale) with regard to spirometry and LABD use. 
However, of these statements, PCPs gave lower ratings to 
their confidence in interpreting spirometry results and recom-
mending an optimal therapeutic regimen for a patient with 
established COPD and mild exertional dyspnea   (Figure 2A). 
Internal medicine physicians reported significantly higher 
confidence than family physicians in both choosing the 
appropriate pulmonary function test for COPD (75.8% vs 
64.7%, P = 0.02) and interpreting spirometry data (67.4% vs 
59.9%, P = 0.02).
Most PCPs believed that spirometry testing is very helpful 
(rated 8–10) in confirming suspicion about a COPD diag-
nosis, but physicians were less sure that spirometry testing 
improves patient outcomes (Figure 2B). Most physicians 
believed that LABDs were helpful in increasing a patient’s 
activity level and quality of life; just under half, however, 
were unsure that LABDs would reduce the risk of future 
COPD exacerbation (Figure 2C).
External barriers to spirometry use
PCPs indicated that there were considerable external 
barriers to obtaining confirmatory spirometry use, as shown 
in Table 3. Nearly half of physicians did not have a work-
ing spirometer in their practice, and nearly 1 in 5 cited 
inadequate access as a significant hindrance to spirometry 
testing, with the most common barrier attributed to lack of a 
working spirometer onsite. Internal medicine physicians were 
more likely than family physicians to encounter a patient’s 
  reluctance to undergo evaluation by spirometry.
Relationship of barriers with COPD 
guideline adherence
Logistic regression models were used to identify predic-
tors of adherence to confirmatory spirometry testing and 
LABD use recommendations, as shown in Table 4. In 
adjusted analysis, independent predictors of PCP adherence 
to spirometry recommendations were agreement with the 
spirometry guideline statement (odds ratio [OR] 3.15), high 
confidence in spirometry data interpretation (OR 1.34), and 
an expectation that spirometry testing would confirm suspi-
cion of COPD (OR 1.55). Physicians indicating an inability 
to integrate onsite spirometry into patient flow were 77% less International Journal of COPD 2011:6
64.7 75.8
67.4
67.4
75.3
57.6
49.5
67.9
59.2
72.8
75.3
65.2
59.9
60.8
63.8
72.7
61.6
53.9
65.7
59.5
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74.6
Confidence in own ability:
To choose pulmonary
function test for COPD
To interpret data on
FEV1 and FVC
To recommend optimal
therapeutic regimen
To gauge response to
pharmacotherapy
02 04 06 08 0 100 02 04 06 08 0 100
02 04 06 08 0 100 02 04 06 08 0 100
02 04 06 08 0 100 02 04 06 08 0 100
Internal medicine Family medicine A
B
C
*
*
For a patient with newly suspected COPD, how helpful is spirometry testing:
For a patient with moderate suspected COPD, how helpful is regular use of a long-acting bronchodilator:
In confirming suspicion
of COPD
In reducing exertional
dyspnea symptoms
In guiding therapeutic
management
In improving patient
health outcomes
In reducing risk of future
COPD exacerbations
In increasing a patient’s
activity level
In increasing a patient’s
quality of life
Rating scales: 1–3 (not confident/helpful) 4–7 (somewhat) 8–10 (very)
Figure 2 Primary care physician assessment of self-efficacy and outcome expectancy of spirometry and long-acting bronchodilator use. Surveyed physicians indicated their 
levels of self-efficacy (A) represented by self-assessment of their own abilities, and outcome expectancy of spirometry (B) and long-acting bronchodilator use (C) defined 
by views on expected helpfulness. Values show percentages of the physicians who rated themselves as “very confident” or that spirometry/long-acting bronchodilators were 
“very helpful” in the given areas.
Note: *Statistical significance between family physicians and internists (P , 0.05).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Table 3 External barriers to spirometry usagea
Overall Family medicine Internal medicine P
Lack of working spirometer onsite 46.8% 46.6% 47.6% 0.85
Lack of spirometry testing nearby 18.4% 17.5% 19.9% 0.55
Inability to integrate onsite  
spirometry into patient flow
35.6% 36.9% 33.5% 0.50
Inadequate reimbursement for  
performing and/or interpreting spirometry
34.8% 35.0% 34.6% 1.00
Patient reluctance to be tested with 
a spirometer
42.4% 38.8% 48.2% 0.04
Cost of spirometry testing to patient 33.0% 35.6% 28.8% 0.12
Note: aValues indicate percentage of physicians indicating these as barriers to confirming chronic obstructive pulmonary disease diagnosis using spirometry.
likely to order spirometry (OR 0.23). The model examining 
  determinants of LABD use showed that PCPs were more 
likely to adhere if they agreed with guideline statements on 
LABD use (OR 1.62) or were confident in gauging patient 
response to pharmacotherapy (OR 1.52). The percentage of 
patients seen with COPD, gender, specialty, or the number of 
years in practice had no significant association with guideline 
adherence for either measure.
Discussion
This study examined PCP attitudes and perceptions to the 
adherence to GOLD COPD practice guidelines. One main International Journal of COPD 2011:6
Table 4 Logistic regression model of physician adherence to COPD guidelines (values indicate odds ratios [95% confidence intervals])
Order spirometry Recommend daily long-
acting bronchodilator
Agreement with guideline statements
When COPD is suspected, the diagnosis should be  
confirmed by spirometry
3.15a (2.03–4.86) 1.13 (0.89–1.44)
For patients with stage 2–3 COPD whose dyspnea during 
daily activities is not relieved with as-needed short-acting 
bronchodilator, a long-acting bronchodilator should be added
1.12 (0.82–1.54) 1.62b (1.16–2.27)
Familiarity with COPD guidelines
Global Initiative for Chronic Obstructive Lung Disease 1.04 (0.91–1.18) 1.02 (0.91–1.15)
American Thoracic Society 1.16 (0.97–1.39) 1.01 (0.87–1.17)
American College of Physicians 0.96 (0.81–1.13) 1.11 (0.96–1.28)
Self-efficacy
Confidence in choosing appropriate pulmonary function  
test for COPD
0.92 (0.69–1.24)
Confidence in interpreting data on FEV1 and FVC 1.34a (1.01–1.78)
Confidence in recommending an optimal therapeutic regimen 1.03 (0.74–1.42)
Confidence in gauging response to pharmacotherapy 1.52a (1.05–2.20)
Outcome expectancy
Spirometry testing in conforming suspicion of COPD 1.55a (1.16–2.07)
Spirometry testing in guiding therapeutic management 0.88 (0.69–1.13)
Spirometry testing in improving patient health outcomes 0.90 (0.73–1.10)
Long-acting bronchodilator in reducing exertional  
dyspnea symptoms
0.93 (0.69–1.26)
Long-acting bronchodilator in reducing risk of future  
COPD exacerbations
0.96 (0.80–1.16)
Long-acting bronchodilator in increasing a patient’s  
activity level
1.17 (0.73–1.86)
Long-acting bronchodilator in increasing a patient’s  
quality of life
1.14 (0.71–1.81)
External barriers to spirometry use
Lack of working spirometer onsite 1.42 (0.76–2.66)
Lack of spirometry testing nearby 1.27 (0.54–2.98)
Inability to integrate onsite spirometry into patient flow 0.23b (0.11–0.46)
Inadequate reimbursement for performing and/or  
interpreting spirometry
0.80 (0.44–1.45)
Patient reluctance to be tested with a spirometer 0.96 (0.55–1.67)
Cost of testing to patient 0.93 (0.52–1.66)
Demographics
Percentage of patients with COPD 1.01 (0.99–1.04) 1.00 (0.98–1.02)
Gender 0.86 (0.46–1.61) 1.32 (0.78–2.24)
Specialty 0.76 (0.42–1.37) 0.99 (0.60–1.62)
Years in practice 0.98 (0.95–1.02) 1.00 (0.97–1.03)
Notes: aP , 0.05; bP , 0.01.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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finding was that only 1 of 4 PCPs adhered to either guideline 
recommendation on spirometry and LABD use more than 
90% of the time. Adherence to guideline recommendations 
of spirometry use was predicted by agreement with the 
recommendations, self-efficacy, perceived outcome expec-
tancy if recommendations were adhered to, and resource 
  availability. Adherence to recommendations of LABD use 
was predicted by agreement with guideline recommenda-
tions and self-efficacy. Survey respondents demonstrated 
greater awareness of COPD practice guidelines disseminated 
by GOLD than to those released by the ATS/ERS. Internal 
medicine physicians indicated more familiarity with COPD 
guidelines than family physicians, possibly in part because 
internal medicine physicians may care for more patients 
with COPD than family practitioners. Internists were most 
familiar with the ACP guidelines.
Less than one-third (31.6%) of PCPs cited high familiarity 
with the GOLD guidelines. This finding rests in stark contrast 
with the more than three-quarters (76.4%) of respondents 
who indicated high familiarity with JNC 7 hypertension International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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guidelines. Although the greater degree of familiarity with 
hypertension guidelines may in part be attributed to the higher 
prevalence of hypertension than of COPD, the disparity 
between guideline awareness for these two common disease 
processes suggests that there may be room for improvement 
in the dissemination of COPD guidelines.
However, increased awareness and dissemination of 
guidelines alone may not necessarily translate into greater 
incorporation of such guidelines into practice. A study by 
Christian et al examining quality of cardiovascular disease 
preventive care found that self-reported incorporation of 
relevant guidelines was lower than awareness levels.15 In their 
original paper on pediatric asthma guidelines, Cabana et al 
found that some element of their model applied to nonadher-
ence to every guideline component they tested,11 including 
familiarity. In our model, familiarity with any guideline did 
not impact adherence to guideline statements. There was 
also discordance between self-reported confidence in pul-
monary function test selection and the importance given to 
spirometry. More than two-thirds (69%) of PCPs indicated 
that they were extremely confident in choosing the appro-
priate pulmonary function test to determine whether COPD 
is present, and a majority (62.6%) cited high confidence in 
ability to interpret spirometry results. Furthermore, although 
60% of PCPs indicated that spirometry testing would be 
extremely helpful in guiding therapeutic management in 
a patient with newly suspected COPD, less than one-third 
(29.6%) strongly agreed that a suspected diagnosis of COPD 
should be confirmed by spirometry. Only about half (52.3%) 
of PCPs indicated that spirometry would be extremely help-
ful in improving health outcomes in a patient with newly 
suspected COPD.
It should be noted that not all COPD practice guidelines 
unequivocally support spirometry. The ATS/ERS guide-
lines support the use of spirometry in primary care practice, 
whereas the ACP guidelines state that there is insufficient 
evidence for the use of spirometry for screening.16,17 One trial 
has examined the use of a combined nurse and physician 
intervention to increase and improve spirometry perfor-
mance but found no difference in outcomes of care between 
treatment and usual care groups.18 The correct diagnosis of 
COPD remained very low (8% in both groups). Another trial 
is currently underway to examine a combined physician–
nurse intervention.19
Our study also examined physician perspectives regard-
ing therapy for COPD. Nearly two-thirds of PCPs indicated 
high confidence in recommending an optimal therapeutic 
regimen and gauging response to pharmacotherapy in 
a patient with established COPD and mild exertional dyspnea. 
Nonetheless, substantially less than half (39.7%) of PCPs 
strongly agreed with the addition of an LABD to the treat-
ment regimen of a patient with stage 2–3 COPD experiencing 
dyspnea despite use of a short-acting bronchodilator. This 
discrepancy between self-reported practice recommenda-
tion and outcome expectancy is somewhat surprising since 
more than two-thirds of respondents indicated that the use 
of an LABD in such a patient would be extremely helpful 
in reducing exertional dyspnea, increasing overall activity 
level, and improving quality of life. Perhaps our findings on 
physician attitudes toward LABDs are tempered by studies 
contemporary to ours that reported potential adverse effects 
from LABD use.20–22 Clinicians may place more weight on 
mortality reduction as an indication for therapy, hence the low 
rate of strong agreement with use of an LABD for COPD.
Limitations of the study
In light of our findings, the model that we used to identify 
potential barriers to guideline adherence may have, in retro-
spect, omitted some important components. The finding of 
integration of office-based spirometry into patient flow as a 
significant barrier suggests that we may not have included 
certain factors to understand why spirometry is perceived 
to have low utility. Due to space constraints within the 
  instrument, our LABD model was less comprehensive than 
the spirometry model and may have left out relevant barriers 
and other determinants of adherence (such as cost–benefit 
and contradictory evidence-based information).
Adherence was measured only by physician self-  reporting 
and not corroborated by chart audits or other external 
checks. Physicians have been shown to have a limited 
ability to accurately self-assess;23 thus, the accuracy of our 
self-efficacy and adherence data may be limited. This study 
was conducted among mainly community-based PCPs who 
quickly responded to an invitation to participate. Although 
the sample differed somewhat from the overall population 
of PCPs within the AMA Physician Masterfile in terms of 
gender, it was statistically similar on all other parameters 
measured. With similar demographics and the use of 500 as 
a representative sample, there is no reason to believe that the 
perceptions of respondents are significantly different from 
those of the overall PCP population. Furthermore, the study 
findings are aligned with previously reported findings that 
self-efficacy, outcome expectancies, and external barriers 
may be more influential determinants of guideline adherence 
than simple guideline familiarity. Given the aforementioned 
limitations, this is the first study to our knowledge to use International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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a framework such as Cabana et al’s in examining barriers to 
COPD guideline adoption.
Clinical implications
Findings from this study offer some useful guidance in 
improving adherence to COPD guidelines. COPD guide-
lines appear to be less well known than guidelines for other 
prevalent diseases. Although guideline familiarity was not 
a predictor of adherence in the model, it may nevertheless 
be an early prerequisite. Efforts to increase the legitimacy 
and utility of this guideline for PCPs may be important. To 
improve guideline adoption, attitudes that can facilitate or 
impede guideline adoption must also be targeted. Agreement 
with guideline recommendations was a significant predictor 
of adherence. However, 1 in 5 PCPs reported ambivalence 
or disagreement with recommendations, and many were 
unconvinced that implementing recommendations would 
be beneficial. Information about specific recommendations 
must therefore simultaneously demonstrate the basis for the 
recommendation and its utility in the primary care setting.
Inadequate confidence in interpreting spirometry data 
may limit the utility of testing, and in this study was an 
independent predictor of nonadherence. Low confidence 
levels were rare, but more than 1 in 3 PCPs had only moder-
ate confidence in their spirometry interpretation skills. This 
may reflect a synthesis, rather than a knowledge gap, and 
may point to difficulty in understanding how spirometry 
data relate to other clinical findings and improve diagnostic 
accuracy. To an extent, guidelines may be able to elaborate 
on the application of spirometry results in practice, but addi-
tional opportunities that allow PCPs to practice and refine 
spirometry interpretation skills may also be needed.
This study drew attention to the importance of measuring 
therapeutic response. Physicians who have difficulty gaug-
ing how patients have responded to therapy were somewhat 
less likely to adhere to recommendations on LABD use. 
LABDs may produce subtle, but meaningful, improvements 
during activity and may reduce exacerbation risk. PCPs may 
need more information regarding how LABDs improve 
respiratory health as well as tools that allow them to gauge 
improvement.
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